Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care

As companies with proficiencies in large-molecule R&D survey the landscape for opportunities, they see increasingly competitive specialist disease markets, or still foggy regulatory pathways for biosimilar products. A few companies have identified what they believe is “white space” in a category that has been back-burnered mainly by an industry bent on cost-efficiency and innovation – primary care.

Large-molecule specialists are emboldened by advances in the selectivity and low-cost manufacture of antibodies and other biological therapies